Main
NSCLC
NON-SMALL CELL LUNG CANCER, NSCLC
Liquid biopsies are gaining momentum in immuno-oncology (IO) as they can be used to rapidly and accurately determine clinical response, especially in the metastatic settingFocusing on patients with non-small cell lung cancer (NSCLC) as a representative example, where both pembrolizumabTo address these challenging questions and further establish the role of ctDNA response as an early endpoint for clinical outcomes with immune checkpoint blockade, we designed a two-stage ctDNA-directed molecular response adaptive clinical trial, with the first stage focusing on answering the questions posed above and reported here.